PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first non-hormonal, non-vascular treatment approved for female sexual dysfunction in the United States.
Free Resource
Get the free Peptide Starter Guide
BPC-157, Semaglutide, TB-500, GHK-Cu, Thymosin Alpha-1 — what the research says and how to source safely. Straight to your inbox.
🔒 No spam. Unsubscribe anytime.
Its mechanism distinguishes it from every other treatment in the category: PT-141 works via melanocortin receptors in the hypothalamus (MC3R and MC4R), influencing central arousal and desire pathways. Unlike sildenafil or tadalafil, it does not require sexual stimulation to trigger a response. The brain initiates it.
For the full deep dive — including the Vyleesi story, off-label use in men, nausea management protocols, and honest clinical assessment — read the complete PT-141 guide →
